Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
We needed to create glucagon analogs to study glucagon biology
GLP-1 receptor agonists bind to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion
L-carnitine is a recognized ingredient of food and dietary supplements
Evidence Summary Current evidence supports the following conclusions: GLP-1 drugs reduce caloric intake Reduced intake may reduce micronutrient consumption Delayed gastric emptying does not equal malabsorption Rapid weight loss may increase lean mass vulnerability Long-term micronutrient outcome data remain limited There is mechanistic plausibility for nutritional risk in certain populations, but no strong evidence of universal depletion across all patients
Timeline based on typical patient experience and clinical trial data
You usually have to submit somewhere else (DSIP for DOD, eRA Commons for NIH, NSPIRES for NASA, etc.)
